Specific transfer factor protects mice against lethal challenge with herpes simplex virus

Viza, D.; Vich, J.M.; Phillips, John C.; Rosenfeld, Fritz; Davies, D. A. L.

doi:10.1016/0008-8749(86)90053-5

Cited by 19 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive responses to TF are confirmed through various tests: Delayed hypersensitivity skin test, reaction to alloantigen, mitogen: specific and non-specific types of T cell, NK cell activity, cytokines activity [2]. TF in osteosarcoma cases increased cell mediated cytotoxicity [13] and in Varicella cases with acute leukaemia in children and Herpes simplex virus improved T cell function [14][15][16]. Elevated C3 level restored to normal, no new infection, absence of eczema was observed in Wiskott -Aldrich syndrome [17].…”

Section: Results -Immunologic and Clinical Responsementioning

confidence: 99%

Untitled

2019

Int J Immunol Immunother

View full text Add to dashboard Cite

Immune Modulating Peptides (IMP) discussed in literature as a universal immunocorrectors with wide areas of usage which balance the immune system without causing global immune suppression or overreaction. The present article aim is to review the effect and drawbacks of IMPs in form of Dialyzable leukocyte Extracts (DLE) or Transfer Factors (TF) during and following chemotherapy, radiotherapy, drugs interactions, cancer response and clinical outcomes in different cases of cancers such as metastatic breast cancer, glioma, prostate cancer, osteosarcoma and others. The considered cases of immune overreaction and IMP's impact include autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and allergic reactions. The most difficult therapeutic decision is to choose the right treatment for patients with cancer and autoimmune diseases as they both attempt to supervise and control the immune system, managing immune cells in opposite sides. As patients with autoimmune disease experience difficulty to stay in such treatment when immune cells stimulated in order to identify and destroy cancer cells the IMP as immunocorrectors become one of the main and only healthy choices. The universal mechanism of IMPs action and the absence of contraindications extend the indications for their use in pediatric practice. This includes the complex treatment of respiratory viral infections, the possibility of using in frequently ill children with clinical signs of immune dysfunction and acute intestinal infections. According to the reports on safety, absence of adverse and side effects along with positive outcome for patients the IMPs considered as valuable immunocorrector.

show abstract

Section: Results -Immunologic and Clinical Responsementioning

confidence: 99%

Untitled

2019

Int J Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Briefly, calves were injected with HSV-1 and HSV-2 live virus and were sacrificed four weeks later, after skin testing had shown satisfactory reactivity to HSV. The activity of TF obtained from the calf lymphocytes was assessed in vitro using the LMT and in vivo using a mouse-protection-to-lethal-HSVchallenge model [24]. The active bovine TF thus obtained was in-vitro-replicated using standard methods established by our laboratory [17,18].…”

Section: Methodsmentioning

confidence: 99%

Transfer factor prevents relapses in herpes keratitis patients: A pilot study

Pizza

Meduri

et al. 1994

Biotherapy

View full text Add to dashboard Cite

Transfer Factor is a dialysable moiety obtained from immune lymphocytes. It has been successfully used for the treatment of several viral infections including labial and genital herpes. In the present study, thirty-three patients with low immune response to HSV antigens and suffering from herpes ocular infections were orally treated with HSV-specific transfer factor (TF). Their relapse index was reduced from 20.1 before treatment to 0.51 after TF administration, with only 6/33 patients relapsing. Although this is not a placebo-controlled-randomized study, the results suggest that TF specific for HSV antigens may be efficacious for preventing relapses of ocular herpes infections as has been the case with genital and labial localisations.

show abstract

“…For instance, using a varicella-zoster-specific (VZV) TF, Steele and co-workers succeeded in protecting leukaemic children from VZV infections during chemotherapy treatments (Steele, 1980;Steele et al, 1980). Prevention against HSV infections was also observed in primates (Steele et al, 1976), rodents (Viza et al, 1986), whereas macaques were protected from the progression of simian AIDS (SAIDS), Viza et al (1988).…”

Section: Transfer Factormentioning

confidence: 99%

Transfer Factor as an Option for Managing the COVID-19 Pandemic

Viza,

Pizza,

De Vinci

et al. 2020

Fol. Biol.

Self Cite

View full text Add to dashboard Cite

Covid-19 or SARS-CoV-2, a new RNA virus with high infectivity, and seemingly low mutability, which appeared in 2019 in the Wuhan province of China, has created a pandemic with dire consequences. At the end of May 2020, it became the first cause of mortality. As no treatment or vaccine may become available before many months, and because occurrence of similar pandemics is only a matter of time, arguments are presented here for testing the effect of transfer factor (TF), an immunomodulator devoid of toxicity, which has been extensively studied in the past for the treatment and prevention of viral infections.

show abstract

Specific transfer factor protects mice against lethal challenge with herpes simplex virus

Cited by 19 publications

References 11 publications

Untitled

Untitled

Transfer factor prevents relapses in herpes keratitis patients: A pilot study

Transfer Factor as an Option for Managing the COVID-19 Pandemic

Contact Info

Product

Resources

About